Zobrazeno 1 - 10
of 192
pro vyhledávání: '"Michael D. Rawlins"'
Autor:
Michael D. Rawlins, Andrew Dillon
Publikováno v:
Significance. 17:38-41
In April 1999, the British government established a new institute, NICE, to assess the clinical and cost-effectiveness of medicines and devices for use by the National Health Service in England. To mark its 21st birthday, NICE's former chair, Michael
Autor:
Michael D Rawlins
Publikováno v:
Medicine. 46:388-392
Good evidence should form the basis for the practice of medicine. Evidence-based medicine encompasses not only pharmaceuticals and devices, but also the appropriate use of diagnostic tests, screening and clinical guideline development. There are, how
Autor:
Michael D. Rawlins
Publikováno v:
British Journal of Clinical Pharmacology. 84:2175-2177
The UK's Life Sciences Strategy provides UK clinical pharmacologists with a unique opportunity to enhance the impact of their discipline on patients and the NHS as well as the pharmaceutical industry. The full benefits of electronic prescribing syste
Autor:
Ian J. Douglas, Sarah J. Tabrizi, Liam Smeeth, Stephen J. W. Evans, Michael D Rawlins, Alice Wexler, Nancy S. Wexler
Publikováno v:
Neuroepidemiology. 46:144-153
Background: Reviews of the epidemiology of Huntington's disease (HD) suggest that its worldwide prevalence varies widely. This review was undertaken to confirm these observations, to assess the extent to which differences in case-ascertainment and/or
Autor:
Michael D Rawlins
Publikováno v:
Journal of the Royal Society of Medicine. 108:211-219
Summary The National Institute for Clinical Excellence was established in 1999. Its original remit was to undertake technology appraisals of (mainly) new interventions and to develop clinical guidelines. In providing both forms of guidance, it was re
Autor:
Michael D Rawlins
Publikováno v:
International Journal of Technology Assessment in Health Care. 30:233-238
Background: The evidence supporting the use of new, or established, interventions may be derived from either (or both) experimental or observational study designs. Although a rigorous examination of the evidence base for clinical and cost-effectivene
Autor:
Michael D Rawlins
Publikováno v:
Clinical Therapeutics. 35(10):1634-1638
THE EVIDENCE BASE Most developed countries, and an increasing number of developing ones, aspire to provide universal access to healthcare for their citizens. All, however, have resource constraints and must inevitably make priorities in determining t
Autor:
Stephen J. W. Evans, Ian J. Douglas, Michael D Rawlins, Liam Smeeth, Sarah J. Tabrizi, Nancy S. Wexler
Publikováno v:
Journal of Neurology, Neurosurgery, and Psychiatry
Background and purpose The prevalence of Huntington9s disease (HD) in the UK is uncertain. Recently, it has been suggested that the prevalence may be substantially greater than previously reported. This study was undertaken to estimate the overall UK
Publikováno v:
Pharmaceuticals Policy & Law. 1999, Vol. 1 Issue 1, p49. 11p.